Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms NICHE
- 07 Mar 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2019.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress, recruitment for this study is ongoing and currently two patients have been enrolled.